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Background
The Global HIV Vaccine Enterprise created a worldwide
alliance of independent organizations dedicated to the
development of preventive HIV vaccines. Global clinical
laboratory work performed under harmonized operations
is a central component for the successful conduct of phase
I–III HIV vaccine clinical trials. In an effort to harmonize
international laboratory operations, the British Associa-
tion of Research Quality Assurance produced GCLP guide-
lines. Subsequently, the Division of AIDS, National
Institute of Allergy and Infectious Diseases, National Insti-
tutes of Health expanded the existing knowledge on GCLP
standards by publishing guidelines on GCLP with
increased implementation guidance. Although both of
these GCLP approaches ensure that laboratory results
from multiple clinical laboratories conducting safety,
diagnostic and endpoint assays are reliable, repeatable,
auditable, and comparable, they differ in the interpreta-
tion of four critical GCLP elements: training, auditing/
accreditation, assay validation, and proficiency testing.
These elements represent crucial stages in the conduct of
GCLP-compliant studies performed by clinical laborato-
ries: from the general set-up (training of personnel and
assay validation) through assay conduction and labora-
tory oversight (audits, proficiency testing and accredita-
tion).
Methods
A workshop was organized to bring together for the first
time experts on GCLP to review, discuss the four elements
listed above and harmonize the two main GCLP
approaches into a single set of recommendations that can
be followed by laboratories in the HIV field and in other
scientific and medical.
Conclusion
The authors reached general consensus on three out of the
four GCLP elements described above, except for the issue
of GCLP laboratory accreditation. The latter is essential for
GCLP compliance and remains controversial as currently,
there is not a public internationally available accrediting
organization acceptable to all parties involved in clinical
trials. The authors wish to raise awareness on the issue of
GCLP accreditation and the need to establish a global
accrediting body.
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